Asthma Trial, Recruiting NCT06419413 Sponsor: AstraZeneca Condition: Asthma
Back to Asthma

Asthma Trial, Recruiting

NCT06419413
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old
  • Your lung function test results (a breathing test called FEV1) meet acceptable levels as defined by international standards
  • You are willing and able to follow the study procedures
  • A doctor has diagnosed you with asthma at least 3 months before your screening appointment

Who may not be able to join:

  • You have had problems with alcohol or drug misuse in the past year
  • You are pregnant at the time of any study assessment
  • You have confusion or difficulty understanding information at the time of signing the consent form
  • You have received certain biological medicines (whether standard treatments or experimental ones) within the past 3 months or within a specific washout period before your first visit, whichever is longer (confirm with trial site)
  • You have had a respiratory infection (such as a cold, chest infection, or similar illness) or related symptoms within 2 weeks before your baseline assessments
  • You have a serious terminal illness, organ failure, or another condition that the study team considers makes participation unsuitable
  • You have taken certain asthma medicines called LTRAs or 5-lipoxygenase inhibitors (for example, montelukast or zileuton) within 1 month or a specific washout period before your baseline visit, whichever is longer (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
8 January 2024
Est. completion
8 October 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Descriptive summary of demographic and subject characteristic, clinical characteristics and functional deliverables.; Descriptive summary of biomarker level.; Statistical clustering of key biomarkers.; FEV1 level; Forced Vital Capacity (FVC); Maximal Mid Expiratory Flow (MMEF); Airway remodeling; Gas trapping; Computed Tomography (CT) Scan

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov